“With Orthocell already sitting on $19.3m in cash, the placement proceeds were not essential. However, the company saw an opportunity to beef up its register to support its global expansion strategy.
“The support of these strategic investors is an endorsement of Orthocell’s science, business strategy and progress in commercialising it’s leading bone and nerve repair products,” chair John Van Der Wielen said.”
Click here to read the article.